NASDAQ:VRAX Virax Biolabs Group (VRAX) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free VRAX Stock Alerts $0.72 +0.01 (+1.41%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.71▼$0.7850-Day Range$0.71▼$1.0752-Week Range$0.70▼$8.54Volume9,315 shsAverage Volume93,499 shsMarket Capitalization$1.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Virax Biolabs Group alerts: Email Address Ad Behind the Markets[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>> About Virax Biolabs Group Stock (NASDAQ:VRAX)Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.Read More VRAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRAX Stock News HeadlinesMarch 22, 2024 | americanbankingnews.comVirax Biolabs Group (NASDAQ:VRAX) Stock Price Down 1.7%March 15, 2024 | prnewswire.comVirax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.December 21, 2023 | finance.yahoo.comVirax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID PatientsDecember 14, 2023 | msn.comVirax Biolabs announces 1-for-10 share consolidationDecember 14, 2023 | finance.yahoo.comVirax Biolabs Group Limited Announces 1-for-10 Share ConsolidationDecember 7, 2023 | msn.comVirax Biolabs files for up to $30M mixed securities shelfOctober 2, 2023 | thestreet.comVirax Biolabs Group Ltd OrdMarch 29, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.September 21, 2023 | finance.yahoo.comVRAX: Virax Biolabs transformative preventive diagnostic platform supports higher stock price.September 12, 2023 | finance.yahoo.comVirax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts WebinarSeptember 1, 2023 | finance.yahoo.comVirax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth MomentumAugust 3, 2023 | finance.yahoo.comNasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 BidJune 21, 2023 | finance.yahoo.comVRAX: Virax Biolabs releases shareholder letter and financial results for the fiscal year ending March 31, 2023.May 5, 2023 | finance.yahoo.comVRAX: UPDATE: Innovative biotechnology company developing a potentially groundbreaking immunology platform based around proprietary T-Cell testing technology.May 4, 2023 | finance.yahoo.comVirax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science ParkApril 21, 2023 | nasdaq.comVirax Biolabs Group Limited Ordinary Shares (VRAX)March 10, 2023 | finance.yahoo.comVirax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesMarch 8, 2023 | benzinga.comVirax Biolabs Group Stock (NASDAQ:VRAX), DividendsMarch 8, 2023 | finance.yahoo.comVirax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesMarch 7, 2023 | msn.comVirax Biolabs Stock Soars On Avian Flu Test Kit Agreement: What's Going On?March 7, 2023 | finance.yahoo.comEXCLUSIVE: Virax Biolabs Starts Distribution Of Avian Flu Test Kits In EuropeMarch 7, 2023 | benzinga.comWhy Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 7, 2023 | prnewswire.comVirax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test KitFebruary 16, 2023 | finance.yahoo.comVRAX: INITIATION: Innovative biotechnology company developing a potentially groundbreaking immunology platform based around proprietary T-Cell testing technologyFebruary 7, 2023 | finance.yahoo.comNew York City scraps COVID vaccine mandate for public-sector workers. ‘This is the right moment for this decision,’ Mayor Adams says.February 6, 2023 | finance.yahoo.comVirax Biolabs to Present at the 2023 BIO CEO & Investor ConferenceSee More Headlines Receive VRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virax Biolabs Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:VRAX CUSIPN/A CIK1885827 Webviraxbiolabs.com Phone44-0-20-7788-7414FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio7.59 Quick Ratio7.56 Sales & Book Value Annual Sales$10,000.00 Price / Sales111.14 Cash FlowN/A Price / Cash FlowN/A Book Value$5.73 per share Price / Book0.13Miscellaneous Outstanding Shares1,550,000Free Float854,000Market Cap$1.11 million OptionableNot Optionable Beta1.00 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. James Foster (Age 39)Chairman & CEO Comp: $347.5kMr. Jason D. Davis (Age 52)Chief Financial Officer Comp: $237.5kMr. Mark James Ternouth (Age 56)Chief Technical Officer & Director Comp: $90kDr. Tomasz Evan George (Age 40)Chief Scientific Officer Comp: $194kDr. Nigel McCracken M.Sc.Ph.D., Chief Operating OfficerMs. Joel YeungAccounting ManagerMr. Clement MonteilHead of Scientific Research & DevelopmentMr. James WangHead of Procurement & SourcingMs. Lily FuHead of Supply ChainMore ExecutivesKey CompetitorsMyMD PharmaceuticalsNASDAQ:MYMDNavidea BiopharmaceuticalsNYSE:NAVBBaudax BioNASDAQ:BXRXSeqLLNASDAQ:SQLCano HealthNYSE:CANOQView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 121,999 shares on 2/13/2024Ownership: 7.871%View All Institutional Transactions VRAX Stock Analysis - Frequently Asked Questions How have VRAX shares performed in 2024? Virax Biolabs Group's stock was trading at $1.46 at the beginning of 2024. Since then, VRAX stock has decreased by 50.9% and is now trading at $0.7170. View the best growth stocks for 2024 here. Are investors shorting Virax Biolabs Group? Virax Biolabs Group saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 15,700 shares, a decline of 74.1% from the February 29th total of 60,600 shares. Based on an average daily volume of 136,600 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.2% of the shares of the company are sold short. View Virax Biolabs Group's Short Interest. When did Virax Biolabs Group's stock split? Virax Biolabs Group shares reverse split on Monday, December 18th 2023. The 1-10 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Virax Biolabs Group IPO? Virax Biolabs Group (VRAX) raised $7 million in an IPO on Thursday, July 21st 2022. The company issued 1,400,000 shares at a price of $5.00 per share. Boustead Securities served as the underwriter for the IPO. Who are Virax Biolabs Group's major shareholders? Virax Biolabs Group's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (7.87%). How do I buy shares of Virax Biolabs Group? Shares of VRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VRAX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.